FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.

Frequently distracted? Your brain rhythms may be to blame

Scientists may have new answers to why pop-ups or notifications grab our attention. Turns out our attention is on a cycle, shifting seven to 10 times per second. This rhythmic occurrence may be crucial for survival, as it ...

page 37 from 40